BON Announces Revolutionary Postbiotic Blood Sugar Solution Nears Patent Launch
Bon Natural Life (Nasdaq: BON) has announced the upcoming launch of a revolutionary patent for a natural postbiotic ingredient targeting blood sugar regulation. The food-derived formula demonstrates significant efficacy in glycemic management, reducing post-meal blood sugar spikes by 15-30% within 1-3 hours when consumed 10-30 minutes before meals.
The solution outperforms existing market alternatives while offering key advantages including food safety and ease of use, factors contributing to high user compliance. The company is pursuing an aggressive global patent protection strategy over the next two years across major markets, aiming to secure their position in the metabolic health sector.
Bon Natural Life (Nasdaq: BON) ha annunciato il prossimo lancio di un brevetto rivoluzionario per un ingrediente postbiotico naturale mirato alla regolazione della glicemia. La formula derivata dagli alimenti dimostra un'efficacia significativa nella gestione glicemica, riducendo i picchi di zucchero nel sangue post-pasto del 15-30% entro 1-3 ore se assunta 10-30 minuti prima dei pasti.
La soluzione supera le alternative attualmente presenti sul mercato offrendo vantaggi chiave, tra cui la sicurezza alimentare e la facilità d'uso, fattori che contribuiscono a un'alta compliance da parte degli utenti. L'azienda sta perseguendo una strategia aggressiva di protezione brevettuale globale nei prossimi due anni nei principali mercati, puntando a consolidare la propria posizione nel settore della salute metabolica.
Bon Natural Life (Nasdaq: BON) ha anunciado el próximo lanzamiento de una patente revolucionaria para un ingrediente postbiótico natural que se enfoca en la regulación del azúcar en sangre. La fórmula derivada de alimentos demuestra una eficacia significativa en la gestión glicémica, reduciendo los picos de azúcar en sangre después de las comidas en un 15-30% dentro de 1-3 horas cuando se consume de 10 a 30 minutos antes de las comidas.
La solución supera las alternativas existentes en el mercado, ofreciendo ventajas clave que incluyen la seguridad alimentaria y la facilidad de uso, factores que contribuyen a una alta adherencia por parte de los usuarios. La empresa está siguiendo una estrategia agresiva de protección de patentes a nivel global durante los próximos dos años en los principales mercados, con el objetivo de asegurar su posición en el sector de la salud metabólica.
본 내추럴 라이프 (Nasdaq: BON)는 혈당 조절을 목표로 하는 자연 유래 포스트바이오틱 성분에 대한 혁신적인 특허 출시를 발표했습니다. 식품에서 유래한 이 포뮬러는 당뇨 관리에서 상당한 효능을 보여주며, 식사 10-30분 전에 섭취할 경우 식사 후 혈당 스파이크를 15-30% 감소시킵니다.
이 솔루션은 기존 시장 대안보다 우수하며, 식품 안전성과 사용 용이성 등의 주요 이점을 제공하여 높은 사용자 준수를 촉진합니다. 이 회사는 향후 2년 동안 주요 시장에서 공격적인 글로벌 특허 보호 전략을 추진하여 대사 건강 분야에서의 입지를 확보할 계획입니다.
Bon Natural Life (Nasdaq: BON) a annoncé le lancement prochain d'un brevet révolutionnaire pour un ingrédient postbiotique naturel ciblant la régulation du sucre dans le sang. La formule dérivée des aliments démontre une efficacité significative dans la gestion glycémique, réduisant les pics de sucre dans le sang après les repas de 15-30% dans les 1 à 3 heures suivant sa consommation 10 à 30 minutes avant les repas.
La solution surpasse les alternatives existantes sur le marché tout en offrant des avantages clés, notamment la sécurité alimentaire et la facilité d'utilisation, des facteurs contribuant à une forte adhésion des utilisateurs. L'entreprise poursuit une stratégie agressive de protection des brevets à l'échelle mondiale au cours des deux prochaines années sur les principaux marchés, visant à sécuriser sa position dans le secteur de la santé métabolique.
Bon Natural Life (Nasdaq: BON) hat die bevorstehende Einführung eines revolutionären Patents für einen natürlichen Postbiotika-Zutaten angekündigt, das auf die Regulierung des Blutzuckers abzielt. Die aus Lebensmitteln abgeleitete Formel zeigt eine signifikante Wirksamkeit im glykemischen Management und reduziert die Blutzucker-Spitzen nach den Mahlzeiten um 15-30% innerhalb von 1-3 Stunden, wenn sie 10-30 Minuten vor den Mahlzeiten eingenommen wird.
Die Lösung übertrifft bestehende Marktalternativen und bietet wichtige Vorteile wie Lebensmittelsicherheit und Benutzerfreundlichkeit, Faktoren, die zu einer hohen Benutzerakzeptanz beitragen. Das Unternehmen verfolgt in den nächsten zwei Jahren eine aggressive globale Patentstrategie in wichtigen Märkten, um seine Position im Bereich der metabolischen Gesundheit zu sichern.
- Innovative product shows 15-30% reduction in post-meal blood sugar spikes
- Product outperforms existing market solutions
- Global patent protection strategy to secure market position
- Product features promote high user adherence
- No specific launch timeline provided
- Patent approvals still pending across major markets
XI’AN, China, March 20, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced a game-changing patent for a natural postbiotic ingredient designed to regulate blood sugar is gearing up for release. The Company has engineered a food-derived postbiotic formula for glycemic management, slated to hit shelves in the near term. When taken 10-30 minutes before meals, this breakthrough product delivers targeted control over post-meal glucose spikes, cutting blood sugar surges by 15
Early data shows its efficacy not only rivals but outperforms leading products already dominating the market. Beyond its precision, the formula boasts a unique edge: It’s food-safe, easy to use, and designed for seamless integration into daily routines-key factors driving high user adherence. With these advantages, the solution is poised to disrupt the post-meal blood sugar control sector and capture significant market share.
Yongwei Hu, Chairman of the Company, said "Backed by a robust IP strategy, the Company is aggressively pursuing global patent protection. Over the next two years, we plan to lock down approvals across top markets, safeguarding our innovation while positioning ourselves for long-term dominance in the fast-growing metabolic health space. This strategic move not only shields the technology but also primes the business for scalable revenue growth and investor appeal."
About Bon Natural Life Limited ("BON")
BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company’s website at http://www.bnlus.com.
For more information, please contact:
Cindy Liu | IR
Email: bonnatural@appchem.cn
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
FAQ
What is the effectiveness of BON's new blood sugar control solution?
How does BON's postbiotic blood sugar formula compare to existing market solutions?
What is BON's patent strategy for their new blood sugar management solution?
When will BON's new postbiotic blood sugar management product be available?
